ArticleKidney research and clinical practice2026
Zinc alpha-2-glycoprotein in peritoneal dialysis effluent correlates with peritoneal transport characteristics, peritonitis rate, and outcome.
Article in Kidney research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThere were limited data on zinc alpha-2-glycoprotein (ZAG) levels and their association with peritoneal characteristics and clinical outcomes in patients undergoing peritoneal dialysis (PD). We aimed to quantify and explore the correlation between ZAG levels in PD effluent (PDE), adipose, and serum samples from PD patients, and to evaluate their association with peritoneal characteristics and outcome.
methodsIncident adult PD patients were enrolled in this prospective cohort study. We measured ZAG levels in PDE, serum, and pre-peritoneal fat tissue samples. Peritoneal characteristics were determined by the standard peritoneal equilibrium test. Primary and secondary outcomes were the 2-year peritonitis rate and peritonitis-related clinical outcomes, respectively.
resultsWe analyzed 126 patients. At baseline, PDE, adipose, and circulating ZAG levels were 1.0 ± 1.2 μg/mL, 15.3 ± 140.5-fold, and 74.4 ± 21.5 μg/mL, respectively. PDE ZAG correlated with adipose ZAG (r = 0.21, p = 0.02), but not with serum ZAG (p = 0.30). PDE ZAG independently predicted small solute peritoneal transport, i.e., dialysate-to-plasma ratio of creatinine at 4 hours (p = 0.01) and mass transfer area coefficient of creatinine (p = 0.04), but not peritoneal protein clearance (p = 0.90). After 222.7 patient-years of follow-up, 40 patients (31.7%) developed 66 peritonitis episodes, and nine patients died. PDE ZAG predicted peritonitis (unstandardized B = 0.446, p < 0.001) and peritonitis-free survival (hazard ratio, 1.36; p = 0.02) after adjustment for confounders.
conclusionPDE ZAG level significantly correlated with peritoneal transport characteristics and was associated with peritonitis and peritonitis-free survival in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.